European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma

• Pier Luigi Zinzani,
• Lionel Karlin,
• John Radford,
• Dolores Caballero,
• Paul Fields,
• Martine E. D. Chamuleau,
• Francesco d’Amore,
• Corinne Haioun,
• Catherine Thieblemont,
• Eva González-Barca,
• Carlos Grande García,
• Peter W. Johnson,
• Gustaaf W. van Imhoff,
• Thomas Ng,
• Karen Dwyer,
• Franck Morschhauser

Affiliations

Pier Luigi Zinzani

University of Bologna, Italy

Lionel Karlin

Centre Hospitalier Lyon-Sud, Pierre-Bénite, France

John Radford

University of Manchester and The Christie NHS Foundation Trust, UK

Dolores Caballero

Hospital Universitario de Salamanca, Spain

Paul Fields

Guy’s Hospital, London, UK

Martine E. D. Chamuleau

Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands

Francesco d’Amore

Aarhus University Hospital, Denmark

Corinne Haioun

Hôpital Henri Mondor, Créteil, France

Catherine Thieblemont

Hôpital Saint Louis, Paris, France

Eva González-Barca

Institut Català d’Oncologia, Barcelona, Spain

Carlos Grande García

Hospital Universitario 12 de Octubre, Madrid, Spain

Peter W. Johnson

NIHR/CRUK Experimental Cancer Medicine Centre, University of Southampton, UK

Gustaaf W. van Imhoff

University Medical Center Groningen, University of Groningen, The Netherlands

Thomas Ng

Kyowa Kirin Pharmaceutical Development, Inc., Galashiels, Scotland

Karen Dwyer

Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ, USA

Franck Morschhauser

Unité GRITA, Université de Lille 2, France